Australia is the first nation to license the medical use of the psychedelic drugs MDMA for post-traumatic stress disorder and psilocybin for depression (Nature 619, 227–228; 2023). There is a danger that this approval could encourage unsupervised uptake worldwide.

Competing Interests

Research of all three authors is financed by the German Federal Ministry of Education and Research (01GP2214). D.R. is a founding member and honorary board chair of MAPS Deutschland. The Charité has received research grants from COMPASS Pathways and MAPS Europe.

Leave a Reply

Your email address will not be published. Required fields are marked *